Reply to thread

Message: [QUOTE="greenmedinfo, post: 2583"] PMID: Pancreas. 2021 Sep 1 ;50(8):1202-1211. PMID: 34714285 Abstract Title: Emodin Alleviates Intestinal Barrier Dysfunction by Inhibiting Apoptosis and Regulating the Immune Response in Severe Acute Pancreatitis. Abstract: OBJECTIVE: The intestinal barrier injury caused by severe acute pancreatitis (SAP) can induce enterogenous infection, further aggravating the inflammatory reactions and immune responses. This study aimed to test the hypothesis that emodin protects the intestinal function and is involved in the immune response in SAP.METHODS: The network pharmacology was established using the Swiss target prediction and pathway enrichment analysis. The SAP mice model was induced by cerulein (50μg/kg) and lipopolysaccharide (10 mg/kg) hyperstimulation. The pharmacological effect of emodin in treating SAP was evaluated at mRNA and protein levels by various methods.RESULTS: The network analysis provided the connectivity between the targets of emodin and the intestinal barrier-associated proteins and predicted the BAX/Bcl-2/caspase 3 signaling pathway. Emodin alleviated the pathological damages to the pancreas and intestine and reduced the high concentrations of serum amylase and cytokines in vivo. Emodin increased the expression of intestinal barrier-related proteins and reversed the changes in the apoptosis-related proteins in the intestine. Simultaneously, emodin regulated the ratio of T helper type 1 (TH1), TH2, TH17,γδ T cells, and interferon γ/interleukin 17 producing γδ T cells.CONCLUSIONS: These findings partly verified the mechanism underlying the regulation of the intestinal barrier and immune response by emodin. [URL='https://www.greenmedinfo.com/article/emodin-alleviates-intestinal-barrier-dysfunction-inhibiting-apoptosis-and-regu']read more[/URL] [/QUOTE]

Verification

Top Bottom

Search

Search

Reply to thread